In our study, we have identified low levels of adropin as promising biomarker of higher risk of AF in HFpEF patients who were optimally treated with GDMT and had target/near target levels of NT-proBNP (<1000 pmol/mL). This evidence concerns the gene NPPB and atrial fibrillation.